The discovery – published today in the prestigious US journal, Cancer Cell – paves the way for the development of therapies that target the early stages of breast cancer.
The research team, headed by Professor Christina Mitchell from the Department of Biochemistry and Molecular Biology, uncovered the gene, called proline-rich inositol polyphosphate 5-phosphatase, or PIPP.
“The discovery of the new tumour suppressor could have significant implications for the way we treat, manage and even potentially detect specific subsets of breast cancers that need targeted or specific treatments related to the gene expression profile in which PIPP expression is lost,” Professor Mitchell said.
Dr Lisa Ooms, the lead author of the paper, said PIPP plays a major role in the initiation and growth of the primary tumour. Together with another already-known oncogene, AKT1, it is implicated in the spread of the disease – the leading cause of breast cancer death, she explained.
The research has three major implications.
The first is that it may help identify a subset of patients that could be targeted with therapies aimed at PIPP and the oncogene pathway PIPP regulates.
Secondly, it may assist in identifying patients at risk of developing secondary cancer, allowing clinicians to make better-informed decisions on whether to implement aggressive or targeted therapy.
Thirdly, the findings could open the way to developing a potential drug that to target the primary cancer and prevent or slow its growth.
Breast cancer is the most common cancer in women, with around 42 Australians diagnosed each day. Once it has spread, chemotherapy is the only option for treatment, and the chances for a complete cure are reduced.